# Therapanacea Sas

- Location (FDA's records): Paris, FR
- FDA decisions: 7 (2021–2025): 7 510(k) clearances
- Names in FDA's records: Therapanacea Sas (4); Therapanacea (3)
- Product codes: MUJ (4), QKB (3)
- 510(k) review time since 2016: median 120 days, against 140 for FDA's reviews in the same codes and years (5 of 7 faster)
- Predicates its devices cite: 11 (5 its own); citations of its devices by later devices: 6 (5 its own)
- Recalls linked to its devices: 0 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Firms whose devices it cites most
- Mirada Medical, Ltd.: 2 (https://510kreport.com/company/mirada-medical)
- Xiamen Manteia Technology, Ltd.: 1 (https://510kreport.com/company/xiamen-manteia-technology)
- Mimvista Corp.: 1 (https://510kreport.com/company/mimvista)
- Varian Medical Systems, Inc.: 1 (https://510kreport.com/company/varian-medical-systems)
- University of Texas, MD Anderson Cancer Center: 1 (https://510kreport.com/company/university-of-texas-md-anderson-cancer-center)

## Firms that cite its devices most
- Seetreat Pty, Ltd.: 1 (https://510kreport.com/company/seetreat)

## Its most-cited devices
- K232479: ART-Plan (2023), cited by 2
- K220813: Art-Plan (2022), cited by 1
- K230023: ART-Plan (2023), cited by 1
- K202700: ART-Plan (2021), cited by 1
- K242822: ART-Plan+ (v.3.0.0) (2025), cited by 1

## Recent decisions
- K253091: ART-Plan+ (v3.1.0) (Dec 23, 2025)
- K242822: ART-Plan+ (v.3.0.0) (Feb 25, 2025)
- K234068: ART-Plan (v.2.2.0) (Apr 22, 2024)
- K232479: ART-Plan (Dec 22, 2023)
- K230023: ART-Plan (Apr 19, 2023)
- K220813: Art-Plan (Jun 17, 2022)
- K202700: ART-Plan (Jan 14, 2021)

Source page: https://510kreport.com/company/therapanacea